Management of Liver Enzyme Elevation After Stopping HIV Antiretroviral Therapy

Laboratory Evaluation and Monitoring

The American College of Physicians recommends assessing for clinical hepatitis symptoms, such as nonspecific gastrointestinal symptoms, flu-like symptoms, hepatomegaly, jaundice, or signs of hepatic failure, in patients who develop liver enzyme elevation after discontinuing HIV antiretroviral therapy 1
The Annals of Internal Medicine suggests checking liver enzymes (AST, ALT, γ-glutamyltransferase) every 2 weeks initially, then monthly for the first 3 months if elevations persist, with a strength of evidence rated as moderate 1, 2
Measuring serum lactate is crucial if lactic acidosis is suspected, using prechilled fluoride-oxalate tubes transported immediately on ice, processed within 4 hours, collected without tourniquet or fist-clenching, with lactate levels 2-5 mmol/dL considered elevated and needing symptom correlation, levels >5 mmol/dL considered abnormal, and levels >10 mmol/dL indicating serious, possibly life-threatening situations 1
Monitoring serum bicarbonate and electrolytes every 3 months is necessary for early identification of increased anion gap, with a strength of evidence rated as low 1

The Centers for Disease Control and Prevention recommends identifying which drug was stopped, as nevirapine discontinuation carries the highest risk of rebound hepatotoxicity, associated with 12.5% incidence of hepatotoxicity, with clinical hepatitis in 1.1% of patients, and can cause fulminant hepatic necrosis and death, with a strength of evidence rated as high 1, 3
Female patients have twice the risk of hepatotoxicity compared to males, with a strength of evidence rated as moderate 1, 3
Protease inhibitor discontinuation, especially ritonavir-containing regimens, can cause hepatotoxicity at any time during or after treatment, with a strength of evidence rated as low 2
Nucleoside analogs, such as didanosine and stavudine, increase the risk of lactic acidosis with hepatic steatosis even after discontinuation, with a strength of evidence rated as moderate 1

The American Association for the Study of Liver Diseases recommends continuing monitoring without immediate intervention for asymptomatic mild elevations (3-5× ULN), as the majority of cases resolve spontaneously, with a strength of evidence rated as low 1, 2
For moderate elevations (5-10× ULN) or symptomatic patients, assessing for clinical hepatitis symptoms, ruling out lactic acidosis syndrome, and considering hepatitis B therapy initiation if coinfected are necessary, with a strength of evidence rated as moderate 1
Severe elevations (>10× ULN) or clinical hepatitis require hospitalization for intensive monitoring, immediate initiation of anti-HBV therapy if coinfected, and treatment of lactic acidosis if present, with a strength of evidence rated as high 1

The Infectious Diseases Society of America recommends avoiding nevirapine in patients with documented hepatotoxicity, as rechallenge can be fatal, with a strength of evidence rated as high 1, 3
Integrase inhibitors, such as dolutegravir, raltegravir, and bictegravir, have superior hepatic safety profiles and are preferred regimens for patients with liver disease history, with a strength of evidence rated as moderate 3, 6, 2
Tenofovir, lamivudine, and raltegravir require no dose adjustment in severe hepatic impairment, with a strength of evidence rated as low 3
Efavirenz-based regimens show lower hepatotoxicity risk than nevirapine, with a strength of evidence rated as moderate 1